All In Biotech

Drug Trial Radar · NCT03927157

Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma

A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults With Severe Uncontrolled Asthma

Last checked: Nov 20, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 405 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

405

Actual

Start

Jun 14, 2019

Primary completion

May 24, 2024

Study completion Aug 13, 2024

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Amgen
First posted
Apr 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Regional, Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Severe Uncontrolled Asthma

Conditions

  • Asthma

Interventions

  • Experimental: TezepelumabBiological

    Tezepelumab subcutaneous injection

  • PlaceboOther

    Placebo subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual Asthma Exacerbation Rate (AERR)Time frame: Randomization to Week 52

Locations

72 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    Baotou, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Changchun, China

  • Research Site

    Changsha, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Chongqing, China

  • Research Site

    Chongqing, China

  • Research Site

    Chongqing, China

  • Research Site

    Fuzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guiyang, China

  • Research Site

    Haikou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hefei, China

  • Research Site

    Hengyang, China

  • Research Site

    Hohhot, China

  • Research Site

    Hohhot, China

  • Research Site

    Huzhou, China

  • Research Site

    Jinan, China

  • Research Site

    Jinhua, China

  • Research Site

    Kunming, China

  • Research Site

    Lanzhou, China

  • Research Site

    Linhai, China

  • Research Site

    Linyi, China

  • Research Site

    Nanchang, China

  • Research Site

    Nanjing, China

  • Research Site

    Nanjing, China

  • Research Site

    Nanjing, China

  • Research Site

    Nanning, China

  • Research Site

    Quanzhou, China

  • Research Site

    Shanghai, China

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.